News and Announcements
Kairos Renewables to Extend Greenfield Development Program Across Southeast Asia with Joint Venture Partner
- Published August 23, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Singapore, 4 August 2021 – Kairos Renewables Pte. Ltd. (Kairos), a utility-scale renewable energy developer focused on Southeast Asia announced it has signed a joint development agreement (JDA) with a confidential Canadian investor.
The focus of the joint venture is to accelerate the development of multiple high potential wind power sites, with specific focus on the Philippines and Vietnam. Acquisition opportunities and the development of solar and energy storage projects will also be explored under the partnership.
Kairos’ joint venture partner is an experienced emerging markets independent power producer seeking to expand their LATAM and Africa portfolio by entering the Asian market. With target growth of 30 GW over the next 5 years, requiring USD 20 billion in new investment, Southeast Asia is the fastest growing renewable energy market in the world.
“Kairos has significant experience and a strong track record in its target markets,” stated Ed Douglas, Managing Director of Kairos. “This partnership will accelerate the growth of our development pipeline to more than 500MW over the next 2 years”.
About Kairos Renewables
Kairos Renewables originates, co-develops and co-finances utility-scale renewable energy projects alongside high-quality international investors. Our co-development model allows us to manage development risk whilst scaling rapidly to meet the demands of the ASEAN renewable energy market.
Kairos provides a fully integrated investment management and technical project delivery solution via its team of 23 seasoned, Asia-experienced project and finance professionals. Based in Singapore, Kairos has offices in Bangkok with an active project footprint extending to Vietnam and Philippines.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
